gemcitabine + nab-paclitaxel: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving gemcitabine + nab-paclitaxel

• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
  NCT06770452 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT06182072 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
  NCT05257993 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 79 Years · Sex: All (male and female) · 4 locations
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  NCT06922591 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
  NCT07436741 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve gemcitabine + nab-paclitaxel?

7 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.